Log in

NYSE:NVRONevro Stock Price, Forecast & News

$114.09
-0.49 (-0.43 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$112.20
Now: $114.09
$114.76
50-Day Range
$114.58
MA: $123.24
$129.85
52-Week Range
$60.51
Now: $114.09
$148.05
Volume279,800 shs
Average Volume348,581 shs
Market Capitalization$3.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Read More
Nevro logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$390.26 million
Book Value$6.98 per share

Profitability

Net Income$-103,690,000.00

Miscellaneous

Employees804
Market Cap$3.88 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Nevro (NYSE:NVRO) Frequently Asked Questions

How has Nevro's stock been impacted by COVID-19 (Coronavirus)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 3.9% and is now trading at $114.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nevro?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nevro.

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) released its earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.78) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.99) by $0.21. The medical equipment provider had revenue of $87.47 million for the quarter, compared to the consensus estimate of $86.70 million. Nevro had a negative net margin of 21.36% and a negative return on equity of 40.67%. Nevro's revenue was up 6.5% on a year-over-year basis. During the same period last year, the company posted ($1.45) earnings per share. View Nevro's earnings history.

What price target have analysts set for NVRO?

12 brokerages have issued twelve-month target prices for Nevro's shares. Their forecasts range from $65.00 to $158.00. On average, they anticipate Nevro's share price to reach $120.83 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price. View analysts' price targets for Nevro.

Has Nevro been receiving favorable news coverage?

Headlines about NVRO stock have been trending very negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nevro earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Nevro.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.04%), Polianta Ltd (0.03%) and FNY Investment Advisers LLC (0.02%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle and Shawn Mccormick. View institutional ownership trends for Nevro.

Which major investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, and Shawn Mccormick. View insider buying and selling activity for Nevro.

Which major investors are buying Nevro stock?

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and FNY Investment Advisers LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle. View insider buying and selling activity for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $114.09.

How big of a company is Nevro?

Nevro has a market capitalization of $3.88 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.